Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMUF Basilea Pharmaceutica	$57.70	$50.83	$47.50 ▼ $57.70	$759.91M	0.23	1 shs	N/A
KYMR Kymera Therapeutics	$44.12 -3.5%	$37.08	$19.45 ▼ $53.27	$2.87B	2.07	623,734 shs	3.80 million shs
MLTX MoonLake Immunotherapeutics	$47.52 +0.5%	$41.82	$31.42 ▼ $58.26	$3.04B	1.24	382,935 shs	923,933 shs
MTSR Metsera	$28.59 -0.4%	$26.70	$12.30 ▼ $37.99	$3.00B	N/A	1.02 million shs	932,237 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMUF Basilea Pharmaceutica	0.00%	0.00%	+21.47%	+6.85%	+19.83%
KYMR Kymera Therapeutics	0.00%	-3.82%	+49.76%	+61.20%	+47.81%
MLTX MoonLake Immunotherapeutics	0.00%	+9.24%	+21.66%	+21.63%	+8.07%
MTSR Metsera	0.00%	-3.41%	+7.85%	+5.03%	+2,858,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	2.8175 of 5 stars	4.5	1.0	0.0	0.0	2.9	1.7	0.0
MLTX MoonLake Immunotherapeutics	2.2606 of 5 stars	3.5	1.0	0.0	0.0	3.3	2.5	0.0
MTSR Metsera	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMUF Basilea Pharmaceutica	4.00	Strong Buy	N/A	N/A
KYMR Kymera Therapeutics	3.00	Buy	$59.61	35.11% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$74.50	56.78% Upside
MTSR Metsera	3.00	Buy	$55.00	92.37% Upside

Current Analyst Ratings Breakdown

Latest BPMUF, MLTX, MTSR, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00
6/20/2025	MTSR Metsera	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$65.00
6/10/2025	MTSR Metsera	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$56.00 ➝ $62.00
6/3/2025	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
6/3/2025	KYMR Kymera Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $64.00
6/3/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$38.00 ➝ $60.00
6/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$49.00 ➝ $79.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMUF Basilea Pharmaceutica	$236.92M	3.21	$6.84 per share	8.43	$6.99 per share	8.25
KYMR Kymera Therapeutics	$47.07M	61.04	N/A	N/A	$12.90 per share	3.42
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$7.09 per share	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	($2.46) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMUF Basilea Pharmaceutica	$88.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.30	N/A	N/A	N/A	N/A	-30.81%	-28.40%	8/6/2025 (Estimated)
MTSR Metsera	-$209.13M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest BPMUF, MLTX, MTSR, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	MLTX MoonLake Immunotherapeutics	-$0.76	-$0.63	+$0.13	-$0.63	N/A	N/A
5/12/2025	Q1 2025	MTSR Metsera	N/A	-$1.03	N/A	-$1.03	N/A	N/A
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMUF Basilea Pharmaceutica	1.18	4.85	4.16
KYMR Kymera Therapeutics	N/A	8.49	8.49
MLTX MoonLake Immunotherapeutics	0.18	21.11	21.11
MTSR Metsera	N/A	6.55	6.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMUF Basilea Pharmaceutica	N/A
KYMR Kymera Therapeutics	N/A
MLTX MoonLake Immunotherapeutics	93.85%
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
BPMUF Basilea Pharmaceutica	N/A
KYMR Kymera Therapeutics	16.01%
MLTX MoonLake Immunotherapeutics	12.05%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMUF Basilea Pharmaceutica	147	13.17 million	N/A	Not Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.30 million	Optionable
MTSR Metsera	81	105.06 million	N/A	N/A

BPMUF, MLTX, MTSR, and KYMR Headlines

Recent News About These Companies

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High? - Nasdaq

June 26, 2025 | nasdaq.com

Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?

June 24, 2025 | zacks.com

Metsera (NASDAQ:MTSR) Trading Down 6.3% - What's Next?

June 23, 2025 | marketbeat.com

Wells Fargo & Company Begins Coverage on Metsera (NASDAQ:MTSR)

June 22, 2025 | americanbankingnews.com

Wells Fargo Initiates Coverage of Metsera (MTSR) with Overweight Recommendation

June 20, 2025 | msn.com

Metsera (NASDAQ:MTSR) Coverage Initiated by Analysts at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Trading 6.4% Higher - Still a Buy?

June 18, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Gap Up - Time to Buy?

June 16, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Down 5.2% - Time to Sell?

June 13, 2025 | marketbeat.com

Metsera (NASDAQ:MTSR) Shares Up 4.5% - Time to Buy?

June 12, 2025 | marketbeat.com

Promising Results Of Amylin Analogs In Obesity: Metsera Case Review

June 12, 2025 | seekingalpha.com

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results

June 11, 2025 | msn.com

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med

June 11, 2025 | medcitynews.comM

Cantor Fitzgerald Estimates Metsera FY2026 Earnings

June 11, 2025 | marketbeat.com

Metsera extends gains after early-stage trial data for obesity therapy

June 10, 2025 | msn.com

Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating

June 10, 2025 | msn.com

Metsera (NASDAQ:MTSR) Shares Gap Up After Analyst Upgrade

June 10, 2025 | marketbeat.com

Guggenheim Issues Positive Forecast for Metsera (NASDAQ:MTSR) Stock Price

June 10, 2025 | marketbeat.com

Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

June 10, 2025 | globenewswire.com

Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

June 9, 2025 | finanznachrichten.de

Metsera shares soar on positive amylin candidate trial results

June 9, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks

BPMUF, MLTX, MTSR, and KYMR Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

$57.70 0.00 (0.00%)

As of 06/27/2025

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Kymera Therapeutics NASDAQ:KYMR

$44.12 -1.59 (-3.48%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$46.62 +2.50 (+5.67%)

As of 04:17 AM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$47.52 +0.23 (+0.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$47.70 +0.18 (+0.38%)

As of 04:05 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Metsera NASDAQ:MTSR

$28.59 -0.12 (-0.42%)

As of 06/27/2025 04:00 PM Eastern

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time